New therapies in diabetes – thiazolidinediones

Bibliography

• HARRIS MI, FLEGAL KM, COWIE CC, et al.: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994 [see comments]. Diabetes Care (1998) 21:518–524.
   PubMed Web of Science ®Google Scholar
• KLEIN R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care (1995) 18:258–268.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, MCGEE DL: Diabetes and cardiovascularrisk factors: the Framingham study. Circulation (1979) 59:8–13.
   PubMed Web of Science ®Google Scholar
• BLOOMGARDEN ZT: International Diabetes Federation meeting, 1997. Issues in the treatment of Type 2 diabetes; sulfonylureas, metformin and troglitazone. Diabetes Care (1998) 21:1024–1026.
   PubMedGoogle Scholar
• RUBIN RJ, ALTMAN WM, MENDELSON DN: Health care expenditures for people with diabetes mellitus, 1992. Clin. Endocrinol. Metab. (1994) 78:809A–809F.
   Google Scholar
• DEFRONZO RA: Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med. (1999) 131:281–303.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ, LEFEBVRE PJ: Troglitazone: antihypergly-cemic activity and potential role in the treatment of Type 2 diabetes. Diabetes Care (1999) 22:1568–1577.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• GERICH JE: The genetic basis of Type 2 diabetes: impaired insulin secretion versus impaired insulin sensitivity. Endocrine Reviews (1998) 1 9 :491–503.
   Google Scholar
• CHIU K, SUDI K, LEE N, CHUANG L: Insulin sensitivity differs among ethnic groups with a compensatory response of beta cell function. Diabetes Care (2000) 23:1353–1358.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: Pathogenesis of Type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. In: 1998 Annual Review of Diabetes. The American Diabetes Association (1998).
   Google Scholar
• MONTAGUE C, ORAHILLY S: The perils of portliness: causes and consequences of visceral adiposity. Diabetes (2000) 49:883–888.
   PubMed Web of Science ®Google Scholar
• OWEN S, JONES N, PATVVARDHAN R: Rosiglitazone reduces gamma- glutamyl transferase level, a marker for visceral and hepatic fat. 60th Scientific Sessions,American Diabetes Association. San Antonio, USA (2000). MEDI 488.
   Google Scholar
• MIYAZAKI Y, MAHANKALI A, MATSUDA M: Effects of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with Type 2 diabetes mellitus (T2 DM) . 60th Scientific Sessions, American Diabetes Association. San Antonio, USA (2000). MEDI 1245.
   Google Scholar
• LAM T, YOSHII H, HABER A: Free fatty acidstime-dependently impair glucose metabolism by mechanisms unrelated to the Randle's cycle. 60th Scientific Sessions, American Diabetes Association. San Antonio, USA (2000). MEDI 1191.
   Google Scholar
• DAY C: Thiazolidinediones: a new class of antidiabetic drugs. Diabetes. Med. (1999) 16:179–192.
   PubMed Web of Science ®Google Scholar
• STUMOVOLI N, NURJHAN N, PERRIELLO G, DAILEY G, GERICH J: Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl. J Med. (1995) 3 3 3:550–554.
   Google Scholar
• JOHNSON A, WEBSTER J, CUM C, HESELTINE L, AGYRAKIM, COOPER B: The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight Type II diabetic patients. Metabolism (1993) 42:1217–1222.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ H: Insulin secretagogues. Diabetes Reviews (1999) 7:139–153.
   Google Scholar
• ROSSETTI L, GIACCARI A, DEFRONZO R: Glucose toxicity. Diabetes Care (1990) 13:610–630.
   PubMed Web of Science ®Google Scholar
• SPIEGELMAN BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 47:507–514.
   PubMed Web of Science ®Google Scholar
• BLOOMGARDEN ZT: American Diabetes Association Annual Meeting, 1998. Treatment of Type 2 diabetes [news]. Diabetes Care (1999) 22:170–174.
   PubMedGoogle Scholar
• FESTA A, D'AGOSTINO R, JR., HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Chronic subclinical inflamma-tion as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 102:42–47.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WU HD, WILLERSON JT, YEH ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation (2000) 101:235–238.
   PubMed Web of Science ®Google Scholar
• UMLAND EM, ROMANELLI AM: Cardiovascular effects of troglitazone. Ann. Pharmacother. (1999) 33:229–232.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, FAULDS D: Troglitazone: a review of its use in the management of Type 2 diabetes mellitus. Drugs (1999) 57:409–438.
   PubMed Web of Science ®Google Scholar
• SERRANO-RIOS M, KLER L, FRITH L: Troglitazone improves insulin resistance compared to metformin (abstract). Diabetes Med. (1997) 14 (Suppl. 4):22.
   Google Scholar
• CLAUDI T, STARKIE M, FRITH L: Troglitazone improves cardiovascular risk profile compared with glibencla-mide (abstract). Diabetes Med. (1997) 14.
   Google Scholar
• HORTON ES, WHITEHOUSE F, GHAZZI MN, VENABLE TC,WHITCOMB RW: Troglitazone in combination withsulfonylurea restores glycemic control in patients with Type 2 diabetes. The Troglitazone Study Group [see comments]. Diabetes Care (1998) 21:1462–1469.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ S, RASKIN P, FONSECA V, GRAVELINE JF: Effect of troglitazone in insulin-treated patients with Type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group [see comments]. N Engl. J. Med. (1998) 338:861–866.
   PubMed Web of Science ®Google Scholar
• BUSE JB, GUMBINER B, MATHIAS NP, NELSON DM, FAJA BW, WHITCOMB RW: Troglitazone use in insulin-treated Type 2 diabetic patients. The Troglitazone Insulin Study Group [see comments]. Diabetes Care (1998) 21:1455–1461.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, JONES NP, PATVVARDHAN R, DEACON LF: Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabetes Med. (2000) 17:287–294.
   PubMed Web of Science ®Google Scholar
• GRUNBERGER G, WESTON WM, PATWARDHAN R: Rosiglitazone once or twice daily improves glycemic control in patients with Type 2 diabetes mellitus. 19th Scientific Session, American Diabetic Association MeetingSan Diego, USA (1999). MEDI 439.
   Google Scholar
• GOMIS R, JONES NP, VALLANCE SE: Low-dose rosiglita-zone provides additional glycemic control when combined with sulfonylureas in Type 2 diabetes. 19th Scientific Session American Diabetic Association MeetingSan Diego, USA (1999). MEDI 266.
   Google Scholar
• FONSECA V, BISWAS N, SALZMAN A: Once daily rosigli-tazone in combination with metformin effectively reduces gyperglycemia in patients with Type 2 diabetes mellitus. 19th Scientific Session, American Diabetic Association Meeting. San Diego, USA (1999). MEDI 431.
   Google Scholar
• RASKIN P, DOLE JF, RAPPAPORT EB: Rosiglitazone improves glycemic control in poorly controlled, insulin-treated Type 2 diabetes. 19th Scientific Session American Diabetic Association Meeting San Diego, USA (1999). MEDI 404.
   Google Scholar
• ARONOFF S, ROSENBLATT S, BRAITHVVAITE S, EGAN J, MATHISEN A, SCHNEIDER R: Pioglitazone hydrochlo-ride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes. Diabetes Care (2000) 23:1605–1611.
   PubMed Web of Science ®Google Scholar
• JOINT NATIONAL COMMITTEE: Joint National Committee Report on the Diagnosis and Treatment of Hypertension (JNC VI). Arch. Intern. Med. (1997) 157:2413–2446.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, WILLIAMS M, DWORKIN L, et al.: Preservingrenal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J Kidney Dis. (2000) 36:646–661.
   PubMed Web of Science ®Google Scholar
• HERBERY LA, BAIN RP, VERNE D, GROUP FTCS: Remission of nephrotic range proteinuria in Type I diabetes. Kidney Intern. (1994) 46:1688–1693.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control withmetformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• IMANO E, KANDA T, NAKATANI Y, et al.: Effect of troglita-zone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care (1 9 9 8) 21:2135-2139.
   Google Scholar
• CLAUDI T, STARKIE M, FRITH L, KLER L, ECKLAND DJA: Troglitazone improves cardiovascular risk profile compared with glibenclamide (abstract). Diabetes Med. (1997) 14 (Suppl. 4):S30.
   Google Scholar
• FREED M, WESTON W, VIBERTI G: Rosiglitazone reduces urinary albumin excretion in Type 2 diabetes. European Association for the Study of Diabetes Scientific Sessions. Brussels, Belgium (1999). MEDI 0368.
   Google Scholar
• BAKRIS G, WESTON W, RAPPAPORT EB: Rosiglitazone produces long-term reductions in urinary albumin excretion in Type 2 diabetes. EASD Scientific Session (1999). MEDI 865.
   Google Scholar
• GHAZZI MN, PEREZ JE, ANTONUCCI TK, et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes (1997) 46:433–439.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T, AKANUMA Y, SHIGETA Y, KANEKO T: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care (1996) 19:151–156.
   PubMed Web of Science ®Google Scholar
• OGIHARA T, RAKUGI H, IKEGAMI H, MIKAMI H, MASUO K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am../ Hypertens. (1995) 8:316–320.
   PubMed Web of Science ®Google Scholar
• KUMAR S, BOULTON AJ, BECK-NIELSEN H, et al.: Troglita-zone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group [published erratum appears in Diabetologia 1996 Oct;39(10):1245]. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• NOZUE T, MICHISHITA I, MINAGAWA F, GENDA A: Troglitazone directly increases HDLcholesterol levels. Diabetes Care (1999) 2 2:355–356.
   Google Scholar
• MURPHY K, SALZMAN A: Rosiglitazone is superior to gluburide in establishing long-term glycemic control in patients with Type 2 diabetes. The Endocrine Society's 82nd Annual Meeting. Toronto, Canada (2000). MEDI 1827.
   Google Scholar
• KAUMI T, HIRANO T, ODAKA H, et al.: VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. Diabetes (1996) 45:806–811.
   PubMedGoogle Scholar
• HOWARD WJ: LDL cholester ol and trogli-tazone therapy [letter; comment]. Diabetes Care (1998) 21:2201–2203.
   PubMedGoogle Scholar
• PYORALA K, PEDERSEN T, KJEKSHUS J, FAERGEMAN 0,OLSSON A, THORGEIRSSON G: The Scandinavian simvastatin survival study (4S) group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: asubgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care (1997) 20:614–620.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments]. N Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• BALFOUR JA, PLOSKER GL: Rosiglitazone. Drugs (1999) 57:921-930; discussion 931–922.
   Google Scholar
• TAKEDA PHARMACEUTICALS AMERICA I: ACTOS full prescribing information. In: Book ACTOS Full Prescribing Information. (28 May 1999).
   Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE, et al.: Troglita-zone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1997) 82:2108–2116.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T, AKANUMA Y, SHIGETA Y, KANEKO T: Effects of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetes. Med. (1996) 13:365–370.
   PubMed Web of Science ®Google Scholar
• KELLY IE, HAN TS, WALSH K, LEAN ME: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with Type 2 diabetes [published erratum appears in Diabetes Care 1999 Mar;22(3):536]. Diabetes Care (1999) 22:288–293.
   PubMed Web of Science ®Google Scholar
• KREIDLER M: Rosiglitazone is effective and well tolerated in patients > 65 years with Type 2 diabetes. 35th Annual Meeting of the European Association for the Study of Diabetes Scientific Sessions. Brussels, Belgium (1999).
   Google Scholar
• KREIDER M, MILLER E, PATEL J: Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with Type 2 diabetes mellitus. 19th Scientific Session, American Diabetic Association Meeting San Diego (1999).
   Google Scholar
• CULKIN KT, PATTERSON SD, JORKASKY DK: Rosiglita-zone does not increase the risk of alcohol-induced hypoglycemia in diet-treated Type 2 diabetics. 19th Scientific Session American Diabetic Association Meeting San Diego (1999).
   Google Scholar
• The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of Type 2 diabetes [see comments] [published erratum appears in Diabetes Care (1999) 22(8):1389]. Diabetes Care (1999) 22:623–634.
   PubMed Web of Science ®Google Scholar
• SALZMAN A, PATEL J: Rosiglitazone is not associated with hepatotoxicity. 19th Scientific Session, American Diabetic Association Meeting San Diego (1999).
   Google Scholar
• SALZMAN A: Rosiglitazone is not associated with hepatoxicity. 35th Annual Meeting of the European Association for the Study of Diabetes Scientific Sessions. Brussels, Belgium (1999).
   Google Scholar
• Physician Desk Reference (2000).
   Google Scholar
• TONTONOZ P, KIM JB, GRAVES RA, SPIEGELMAN BM: ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differen-tiation. Mol. Cell. Biol. (1993) 13:4753–4759.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA C, WANG X, BRIGGS MR, et al.: SREBP-1, a basic-helix -loop -helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell (1993) 75:187–197.
   PubMed Web of Science ®Google Scholar